Skip to main
EVAX
EVAX logo

EVAX Stock Forecast & Price Target

EVAX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evaxion AS has demonstrated a significant enhancement in the prediction accuracy of its PIONEER AI model, now achieving 81% immunogenicity for predicted neoantigens, thus reinforcing its leadership in neoantigen cancer vaccine development. The impressive overall response rate (ORR) of 75% for patients treated with the combination of EVX-01 and pembrolizumab, coupled with a favorable safety profile, positions the company favorably compared to competitors, such as Moderna. Additionally, the data reveals not only sustained responses in patients undergoing treatment but also deepened responses, contributing to a robust outlook for Evaxion’s innovative immunotherapy pipeline targeting critical unmet medical needs in oncology and infectious diseases.

Bears say

Evaxion AS's stock has shown a negative reaction despite a strong data update on its EVX-01 product, indicating a disconnect between the company's advancements and investor expectations. The lack of a clear indication of EVX-01’s contribution may have heightened investor skepticism regarding the company's ability to deliver on its promises within its oncology pipeline. This situation raises concerns about market confidence in Evaxion's financial sustainability and the execution of its innovative strategies.

EVAX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evaxion Biotech A/S (EVAX) Forecast

Analysts have given EVAX a Strong Buy based on their latest research and market trends.

According to 3 analysts, EVAX has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evaxion Biotech A/S (EVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.